Hedgepath Pharmaceuticals Inc (HPPI) 0.2001 $HPPI
BUYINS.NET Issues HedgePath Pharmaceuticals (HPPI) SqueezeTrigger Report
PR Newswire - Wed Jun 15, 7:00AM CDT
HedgePath Pharmaceuticals, Inc. (HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that BUYINS.NET, http://www.buyins.net/, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on HedgePath Pharmaceuticals (OTC: HPPI) after releasing the latest short sale data through June 10, 2016. The total aggregate number of shares shorted since August 2009 is approximately 4.6 million shares. Approximately 28.39% of total trading volume is short selling. The SqueezeTrigger price for all HPPI shares shorted is $0.298. A short squeeze is expected to begin when shares of HPPI cross above the $0.298 SqueezeTrigger Price.
FDA Grants Orphan Drug Designation to SUBA(TM)-Itraconazole for Treatment of Patients with BCCNS
PR Newswire - Thu Jun 02, 8:00AM CDT
HedgePath Pharmaceuticals, Inc. (OTCQB: HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that it has received notice of Orphan Drug Designation for treatment of patients with Basal Cell Carcinoma Nevus Syndrome (BCCNS) with its oral formulation of SUBA-Itraconazole Capsules.
HedgePath Pharmaceuticals Announces Completion of $5.5 Million Private Placement Offering
PR Newswire - Wed Jun 01, 8:00AM CDT
HedgePath Pharmaceuticals, Inc. (OTCQB: HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that it has completed its previously announced $5.5 million private placement offering. The company conducted the first closing of this offering on April 11, 2016. Offering expenses are estimated to be approximately $100,000.
HedgePath Pharmaceuticals Announces Commencement of Patient Treatment in its Phase II(b) Clinical Trial
PR Newswire - Tue Sep 29, 7:00AM CDT
HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that initial patients have received base-line screening and the first of those patients has begun dosing in HPPI's Phase II(b) clinical trial examining SUBA(TM) Itraconazole Capsules as a potential therapy for basal cell carcinoma (BCC) in patients with basal cell carcinoma nevus syndrome (BCCNS), also known as Gorlin's Syndrome.
HedgePath Pharmaceuticals To Receive $2.5 Million in Funding From Mayne Pharma
PR Newswire - Mon May 18, 8:00AM CDT
HedgePath Pharmaceuticals, Inc., (OTCQB: HPPI) a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that it has entered into a definitive agreement with an affiliate of Mayne Pharma Group Limited (ASX: MYX) under which Mayne Pharma will invest $2.5 million in HPPI in a private common stock and warrant financing. The closing of the financing is expected to occur within five business days.
HedgePath Pharmaceuticals Receives IND Clearance to Commence Development of its Proposed Cancer Treatment
PR Newswire - Tue Dec 16, 8:00AM CST
HedgePath Pharmaceuticals, Inc. (OTCQB: HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that it received clearance of its first Investigational New Drug (IND) Application from the U.S. Food and Drug Administration (FDA).
HedgePath Pharmaceuticals Files IND Application
PR Newswire - Tue Nov 18, 8:00AM CST
HedgePath Pharmaceuticals, Inc. (OTCQB: HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that it filed an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration (FDA) on Friday, November 14, 2014.
BUYINS.NET Issues HedgePath Pharmaceuticals (HPPI) SqueezeTrigger Report
PR Newswire - Wed Jun 15, 7:00AM CDT
HedgePath Pharmaceuticals, Inc. (HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that BUYINS.NET, http://www.buyins.net/, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on HedgePath Pharmaceuticals (OTC: HPPI) after releasing the latest short sale data through June 10, 2016. The total aggregate number of shares shorted since August 2009 is approximately 4.6 million shares. Approximately 28.39% of total trading volume is short selling. The SqueezeTrigger price for all HPPI shares shorted is $0.298. A short squeeze is expected to begin when shares of HPPI cross above the $0.298 SqueezeTrigger Price.
FDA Grants Orphan Drug Designation to SUBA(TM)-Itraconazole for Treatment of Patients with BCCNS
PR Newswire - Thu Jun 02, 8:00AM CDT
HedgePath Pharmaceuticals, Inc. (OTCQB: HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that it has received notice of Orphan Drug Designation for treatment of patients with Basal Cell Carcinoma Nevus Syndrome (BCCNS) with its oral formulation of SUBA-Itraconazole Capsules.
HedgePath Pharmaceuticals Announces Completion of $5.5 Million Private Placement Offering
PR Newswire - Wed Jun 01, 8:00AM CDT
HedgePath Pharmaceuticals, Inc. (OTCQB: HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that it has completed its previously announced $5.5 million private placement offering. The company conducted the first closing of this offering on April 11, 2016. Offering expenses are estimated to be approximately $100,000.
HedgePath Pharmaceuticals Announces Commencement of Patient Treatment in its Phase II(b) Clinical Trial
PR Newswire - Tue Sep 29, 7:00AM CDT
HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that initial patients have received base-line screening and the first of those patients has begun dosing in HPPI's Phase II(b) clinical trial examining SUBA(TM) Itraconazole Capsules as a potential therapy for basal cell carcinoma (BCC) in patients with basal cell carcinoma nevus syndrome (BCCNS), also known as Gorlin's Syndrome.
HedgePath Pharmaceuticals To Receive $2.5 Million in Funding From Mayne Pharma
PR Newswire - Mon May 18, 8:00AM CDT
HedgePath Pharmaceuticals, Inc., (OTCQB: HPPI) a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that it has entered into a definitive agreement with an affiliate of Mayne Pharma Group Limited (ASX: MYX) under which Mayne Pharma will invest $2.5 million in HPPI in a private common stock and warrant financing. The closing of the financing is expected to occur within five business days.
HedgePath Pharmaceuticals Receives IND Clearance to Commence Development of its Proposed Cancer Treatment
PR Newswire - Tue Dec 16, 8:00AM CST
HedgePath Pharmaceuticals, Inc. (OTCQB: HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that it received clearance of its first Investigational New Drug (IND) Application from the U.S. Food and Drug Administration (FDA).
HedgePath Pharmaceuticals Files IND Application
PR Newswire - Tue Nov 18, 8:00AM CST
HedgePath Pharmaceuticals, Inc. (OTCQB: HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that it filed an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration (FDA) on Friday, November 14, 2014.
